KR960007610A - N-아실-5-플루오로시티딘 유도체의 제조 방법 - Google Patents

N-아실-5-플루오로시티딘 유도체의 제조 방법 Download PDF

Info

Publication number
KR960007610A
KR960007610A KR1019950026517A KR19950026517A KR960007610A KR 960007610 A KR960007610 A KR 960007610A KR 1019950026517 A KR1019950026517 A KR 1019950026517A KR 19950026517 A KR19950026517 A KR 19950026517A KR 960007610 A KR960007610 A KR 960007610A
Authority
KR
South Korea
Prior art keywords
acyl
formula
preparing
fluorocytidine
aralkyl
Prior art date
Application number
KR1019950026517A
Other languages
English (en)
Other versions
KR100335542B1 (ko
Inventor
로버트 브린크만 허버트
칼라리티스 파나이오티스
프란시스 모리세이 존
Original Assignee
프리돌린 클라우스너, 롤란드 보러
에프. 호프만-라 롯슈 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너, 롤란드 보러, 에프. 호프만-라 롯슈 아크티엔게젤샤프트 filed Critical 프리돌린 클라우스너, 롤란드 보러
Publication of KR960007610A publication Critical patent/KR960007610A/ko
Application granted granted Critical
Publication of KR100335542B1 publication Critical patent/KR100335542B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

하기 일반식(I)의 공지 항종양제인 N4-아실-5'-데옥시-5-플루오로시티딘 유도체는 일반식(Ⅱ)의 신규 중간화합물로부터 제조된다:
상기식에서, R은 알킬, 사이클로알킬, 알케닐, 아르알킬 또는 아릴이다.

Description

N-아실-5-플루오로시티딘 유도체의 제조 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 수성 또는 불활성 유기 용매중에서 하기 일반식(Ⅱ)의 화합물을 유기 또는 무기 염기로 처리함을 포함하는, 하기 일반식(I)의 N4-아실-5'-데옥시-5-플루오로시티딘 유도체의 제조 방법.
    상기식에서, R은 알킬, 사이클로알킬, 알케닐, 아르알킬 또는 아릴이다.
  2. 하기 일반식(Ⅱ)의 화합물:
    상기식에서, R은 알킬, 사이클로알킬, 알케닐, 아르알킬 또는 아릴이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950026517A 1994-08-26 1995-08-25 N-아실-5-플루오로시티딘유도체의제조방법 KR100335542B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/296,842 US5476932A (en) 1994-08-26 1994-08-26 Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US08/296842 1994-08-26
US08/296,842 1994-08-26

Publications (2)

Publication Number Publication Date
KR960007610A true KR960007610A (ko) 1996-03-22
KR100335542B1 KR100335542B1 (ko) 2002-11-08

Family

ID=23143805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950026517A KR100335542B1 (ko) 1994-08-26 1995-08-25 N-아실-5-플루오로시티딘유도체의제조방법

Country Status (9)

Country Link
US (1) US5476932A (ko)
EP (1) EP0698611B1 (ko)
JP (1) JP3986574B2 (ko)
KR (1) KR100335542B1 (ko)
CN (1) CN1053194C (ko)
AT (1) ATE185811T1 (ko)
DE (1) DE69512851T2 (ko)
DK (1) DK0698611T3 (ko)
ES (1) ES2138691T3 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060042198A (ko) * 2004-02-26 2006-05-12 미쓰이 가가쿠 가부시키가이샤 Ｎ4─아실시티딘 유도체의 금속염, 및 이 금속염을 사용하는 ｎ4─아실시티딘 유도체의 제조 방법

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
WO2003097609A1 (en) 2002-05-15 2003-11-27 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
KR100851272B1 (ko) * 2003-12-22 2008-08-08 에프. 호프만-라 로슈 아게 플루오로시티딘 유도체에 대한 방법
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
US10603314B2 (en) 2005-02-03 2020-03-31 The General Hospital Corporation Method for treating gefitinib resistant cancer
EP1868608A2 (en) * 2005-04-01 2007-12-26 F. Hoffmann-Roche AG Method for administration of capecitabine
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
AR057854A1 (es) 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
WO2009022435A1 (ja) * 2007-08-15 2009-02-19 Japan Absorbent Technology Institute 吸収体製品およびその製造方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009094847A1 (fr) * 2007-12-28 2009-08-06 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine
WO2009082846A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
CN101469008B (zh) * 2007-12-29 2013-08-07 上海特化医药科技有限公司 卡培他滨羟基衍生物、其制备方法和用于制备卡培他滨
WO2009082844A1 (fr) * 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
US20090209754A1 (en) * 2008-01-03 2009-08-20 Macdonald Peter Lindsay Process for the preparation of capecitabine
HUE028327T2 (en) 2008-06-06 2017-02-28 Neurmedix Inc A process for the preparation of 17-alkynyl-7-hydroxy steroids and related compounds
PT2310011E (pt) 2008-06-17 2013-10-07 Wyeth Llc Combinações antineoplásicas contendo hki-272 e vinorelbina
LT2326329T (lt) 2008-08-04 2017-05-25 Wyeth Llc 4-anilin-3-cianochinolinų ir kapecitabino antinavikiniai deriniai
AU2010234968B2 (en) 2009-04-06 2015-05-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
KR102090740B1 (ko) 2011-10-03 2020-03-18 엠엑스 아쥬바크 에이비 암 치료 및 식품 관련 화합물을 포함하는 의학 분야에서 양친매성 또는 소수성 분자를 위한 나노입자, 제조 방법 및 담체로의 용도
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
CN104926901B (zh) * 2015-06-15 2018-04-20 广安凯特制药有限公司 一种卡培他滨关键中间体的合成方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
KR20230004716A (ko) 2020-04-21 2023-01-06 리간드 파마슈티칼스 인코포레이티드 뉴클레오티드 프로드러그 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000997A1 (en) * 1980-09-22 1982-04-01 Johannson R Carriage assembly with shiftable forks
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
TW254946B (ko) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060042198A (ko) * 2004-02-26 2006-05-12 미쓰이 가가쿠 가부시키가이샤 Ｎ4─아실시티딘 유도체의 금속염, 및 이 금속염을 사용하는 ｎ4─아실시티딘 유도체의 제조 방법

Also Published As

Publication number Publication date
DE69512851T2 (de) 2000-05-04
CN1053194C (zh) 2000-06-07
ATE185811T1 (de) 1999-11-15
CN1126726A (zh) 1996-07-17
KR100335542B1 (ko) 2002-11-08
DE69512851D1 (de) 1999-11-25
US5476932A (en) 1995-12-19
JPH0859687A (ja) 1996-03-05
ES2138691T3 (es) 2000-01-16
JP3986574B2 (ja) 2007-10-03
DK0698611T3 (da) 2000-03-27
EP0698611A1 (en) 1996-02-28
EP0698611B1 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
KR960007610A (ko) N-아실-5-플루오로시티딘 유도체의 제조 방법
KR960704919A (ko) 신규인 펩티드 유도체 (novel peptide derivative)
KR890011884A (ko) 캠프토데신 유도체
KR927003540A (ko) 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체
KR900004722A (ko) 푸마길롤 유도체
KR830007487A (ko) 심장질환치료제의 제조방법
KR920701162A (ko) 퀴놀린 유도체, 당해 유도체를 함유하는 항궤양제 및 당해 유도체의 제조방법
KR950702976A (ko) 벤조피란 및 벤족사진 유도체[benzopyran and benzoxazine derivatives]
KR890007730A (ko) 허혈성 심질환 치료제
KR830006198A (ko) 시클로헥산 유도체의 제조방법
KR920701120A (ko) 치환된 비시클로헵탄디온 유도체
KR960010644A (ko) 캠프토테신, 그 제조방법 및 항 종양제
KR900003177A (ko) 테트라시클릭계 우울증 치료제
KR840008342A (ko) 모르포린 유도체의 제조방법
KR950032183A (ko) 글루코피라노사이드 벤조티오펜
KR900701762A (ko) 테트라히드로피리미딘 유도체
KR950701312A (ko) 신규 4급 암모늄염 및 약제로서 그의 사용
KR860002482A (ko) 디페닐 에테르 이민 유도체 제조방법
KR970705614A (ko) 트리아릴메탄 올리고머 염료(oligomer triarylmethane dyes)
KR890016006A (ko) 피롤 유도체
KR860006450A (ko) 5-클로로-1,3,4-티아디아졸-2-일옥시-아세트-아미드의 제조방법
KR900000345A (ko) 1-할로 1-아졸일에탄유도체 및 이들을 함유하는 살균제
KR970001309A (ko) N-치환된 시스-n-프로페닐-아세트아미드 및 그의 제조방법
KR870007908A (ko) 인덴류 화합물의 제조방법
KR900003196A (ko) 뉴클레오티드 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120329

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20130329

Year of fee payment: 12

EXPY Expiration of term